| Literature DB >> 21764221 |
M H A Jansen1, D G van Vuurden, W P Vandertop, G J L Kaspers.
Abstract
Patients with diffuse intrinsic pontine gliomas (DIPG) have a poor prognosis. Although DIPG constitute only 10-15% of all pediatric brain tumors, they are the main cause of death in this group. Despite 26 clinical trials in newly diagnosed DIPG in the past 5years (including several targeted agents), there is no clear improvement in prognosis. However, knowledge on DIPG biology is increasing, mainly due to the (re)introduction of biopsies and autopsies, the possibility of gene expression profiling, and the development of in vivo models. Translation of this knowledge into clinical trials in combination with improved drug distribution methods may eventually lead to more effective treatment of this devastating disease. 2011 Elsevier Ltd. All rights reserved.Entities:
Mesh：
Substances：
Year: 2011 PMID： 21764221 DOI： 10.1016/j.ctrv.2011.06.007
Source DB: PubMed Journal: Cancer Treat Rev ISSN： 0305-7372 Impact factor: 12.111